| Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248) |
|---|
| 05/16/2007 | CN1964990A Antibodies specific for glycoprotein VI and methods of producing these antibodies |
| 05/16/2007 | CN1964987A Inhibitors of REGIII proteins as asthma therapeutics |
| 05/16/2007 | CN1964741A Methods of using molecules related to organic cation transporter 3 (OCT3) for treating depression, anxiety neuroses, drug dependencies, and other similar mental disorders |
| 05/16/2007 | CN1964740A Methods and compositions for treating and preventing diseases associated with alphaVbeta5 integrin |
| 05/16/2007 | CN1964739A Uses of anti-CTLA-4 antibodies |
| 05/16/2007 | CN1964738A Monoclonal antibodies to hepatocyte growth factor |
| 05/16/2007 | CN1964737A Methods of using IL-1 antagonists to treat autoinflammatory disease |
| 05/16/2007 | CN1964630A Regulation of food intake and glucose production by modulation of long-chain fatty acyl-coa levels in the hypothalamus |
| 05/16/2007 | CN1962868A Japanese blood fluke SDISP gene and its clone, expression and application |
| 05/16/2007 | CN1962692A Staphylococcus aureus enterotoxin E and its preparation and uses |
| 05/16/2007 | CN1961961A A pharmaceutical formulation and preparation process thereof |
| 05/16/2007 | CN1316022C Novel chimeric TNF ligands |
| 05/16/2007 | CN1315537C LIM Mineralization protein splice variants |
| 05/16/2007 | CN1315536C Novel vaccine of tumor antigen, its preparation method and vaccine composition |
| 05/16/2007 | CN1315535C Adjuvant for improving hepatitis B vaccine immune effect and preparing method thereof |
| 05/16/2007 | CN1315534C Vaccine for respiratory and reproductive system infections in cattle |
| 05/16/2007 | CN1315533C Inactivate pig parvovirus disease oil emulsion vaccine |
| 05/15/2007 | US7217812 Extraneous DNA sequence that facilitates hantavirus gene expression |
| 05/15/2007 | US7217799 Antibodies that recognize the 85P1B3 protein useful in treatment and detection of cancer |
| 05/15/2007 | US7217798 has an increased (or decreased) in vivo half-life by virtue of the presence of a modified IgG constant domain (preferably from a human IgG), or FcRn-binding portion thereof (preferably the Fc or hinge-Fc domain) |
| 05/15/2007 | US7217796 Neutralizing human anti-IGFR antibody |
| 05/15/2007 | US7217792 an antibody reactive with the isolated polypeptide induces proliferation of peripheral blood lymphocytes in the presence of an antibody reactive with CD3; used to treat autoimmune diseases and allergic diseases |
| 05/15/2007 | US7217791 a polypeptide conjugated to a Streptococcus pneumoniae capsular polysaccharide; an expression vector encoding a Streptococcus pneumoniae pneumolysin polypeptide that lacks hemolytic activity; vaccine; genetic vaccine; antigen |
| 05/15/2007 | US7217786 Polypeptide ESDN, polynucleotides encoding the polypeptide, and utility of the polypeptide |
| 05/15/2007 | US7217784 Polypeptide can be used for generating antibodies, detecting virus infection, and producing vaccines |
| 05/15/2007 | US7217738 β2-adrenergic receptor agonists |
| 05/15/2007 | US7217718 Administering an immunosuppressant; therapy for autoimmune disease |
| 05/15/2007 | US7217713 N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase |
| 05/15/2007 | US7217700 Chemokines as adjuvants of immune response |
| 05/15/2007 | US7217694 Inhibitors of IAPP fibril formation and uses thereof |
| 05/15/2007 | US7217541 Culuring transgenic cells which codes bactericides; genetic vaccines |
| 05/15/2007 | US7217538 Nucleic acid molecule containing a nucleotide sequence encoding CaEss1 (candida albicans) gene or having at least 70% homology; antiproliferative application |
| 05/15/2007 | US7217535 Immunoassay diagnosis of susceptibility to atherosclerosis by analyzing blood for presence of enzyme using polyclonal or monoclonal antibodies; elevated levels are indicative of susceptibility |
| 05/15/2007 | US7217526 identifying T cells in a sample that become activated in the presence of a vaccinia or variola virus using immunogenic mutant or fragment of peptide 165 as a CD8 T cell epitope |
| 05/15/2007 | US7217428 For controlled release of compounds through the use of a chemically sensitive cantilever |
| 05/15/2007 | US7217420 Protective formulation that prevents virulent Mycoplasma gallisepticum infection in birds of the order Galliformes; formulation comprises a protective amount of live MG strain K5054 or derivatives |
| 05/15/2007 | US7217419 Vaccine for preventing cervical cancer |
| 05/15/2007 | US7217418 Administering an attenuated dengue-1 (DEN-1) virus composition |
| 05/15/2007 | US7217416 Use of gamma globulin for the topical treatment of lesions of dermatitis |
| 05/15/2007 | US7217415 NADP-dependent glyceraldehyde-3-phosphate dehydrogenase for therapeutic use |
| 05/15/2007 | CA2515166C Direct molecular cloning of a modified eukaryotic cytoplasmic dna virus genome |
| 05/15/2007 | CA2332131C Serine protease-specific monoclonal antibody and utilization thereof |
| 05/15/2007 | CA2279919C Arthrobacter vaccine and its use against renibacterium salmoninarum |
| 05/15/2007 | CA2255540C Antigen binding fragments that specifically detect cancer cells, nucleotides encoding the fragments, and use thereof for the prophylaxis and detection of cancers |
| 05/15/2007 | CA2249736C Caprine arthritis-encephalitis virus provides immunoprotection against hiv-1 infection |
| 05/15/2007 | CA2176948C Chaperonin 10 |
| 05/15/2007 | CA2168885C Vaccine compositions |
| 05/15/2007 | CA2156397C Rapamycin assay |
| 05/15/2007 | CA2149922C Genetically engineered glutaminase and its use in antiviral and anticancer therapy |
| 05/15/2007 | CA2130452C Altered antibodies, products and processes relating thereto |
| 05/15/2007 | CA2094705C Pharmaceutical composition for treating or preventing malign tumors |
| 05/15/2007 | CA2087958C Transferrin binding proteins from neisseria gonorrhoeae and neisseria meningitidis |
| 05/15/2007 | CA2065414C Treatment of autoimmune disease |
| 05/15/2007 | CA2011633C Intercellular adhesion molecule - 2 and its binding ligands |
| 05/10/2007 | WO2007053810A2 Liposomally encapsulated reduced glutathione, including with other pharmacologic preparation, capable of administration as an oral, topical, intraoral or transmucosal, preparation, for reversal and prevention of oxidation of cholesterol and of low density lipoprotein |
| 05/10/2007 | WO2007053781A2 Compositions with antigens adsorbed to calcium phosphate |
| 05/10/2007 | WO2007053767A1 Uses of anti-cd40 antibodies |
| 05/10/2007 | WO2007053718A1 Antibodies and immunotoxins that target human glycoprotein nmb |
| 05/10/2007 | WO2007053661A2 Uses of anti-cd40 antibodies |
| 05/10/2007 | WO2007053487A2 Methods and devices for detection of the strain of a pathogen |
| 05/10/2007 | WO2007053447A2 Compositions and methods for the treatment and prevention of fibrotic, inflammatory and neovascularization conditions |
| 05/10/2007 | WO2007053446A2 Use of vaccines for the treatment/ prevention of the transmission of influenza pathogens between species |
| 05/10/2007 | WO2007053189A2 Compositions and methods for altering immune function |
| 05/10/2007 | WO2007053188A2 Production of multivalent virus like particles |
| 05/10/2007 | WO2007053183A2 Chloroplasts engineered to express pharmaceutical proteins |
| 05/10/2007 | WO2007053176A2 Method of protecting against staphylococcal infection |
| 05/10/2007 | WO2007053076A1 A method for preparing a textile material and a textile material thus prepared and produced |
| 05/10/2007 | WO2007052850A1 USE OF COMBINATION OF ANTI-ANGIOGENIC SUBSTANCE AND c-kit KINASE INHIBITOR |
| 05/10/2007 | WO2007052849A1 USE OF COMBINATION OF ANTI-ANGIOGENIC SUBSTANCE AND c-kit KINASE INHIBITOR |
| 05/10/2007 | WO2007052168A2 Fed batch culture methods for streptococci |
| 05/10/2007 | WO2007052165A2 A lentiviral vector-based vaccine |
| 05/10/2007 | WO2007052163A2 Cell-derived viral vaccines with low levels of residual cell dna by beta-propiolactone treatment |
| 05/10/2007 | WO2007052061A2 Emulsions with free aqueous-phase surfactant as adjuvants for split influenza vaccines |
| 05/10/2007 | WO2007052060A1 Influenza vaccines extemporaneously adsorbed to aluminium adjuvants |
| 05/10/2007 | WO2007052059A2 Changing th1/th2 balance in split influenza vaccines with adjuvants |
| 05/10/2007 | WO2007052058A1 Influenza vaccines including combinations of particulate adjuvants and immunopotentiators |
| 05/10/2007 | WO2007052057A2 Adminstration routes for priming/boosting with influenza vaccines |
| 05/10/2007 | WO2007052056A1 Adjuvanted influenza vaccines including cytokine-inducing agents |
| 05/10/2007 | WO2007052055A1 Adjuvanted vaccines with non-virion antigens prepared from influenza viruses grown in cell culture |
| 05/10/2007 | WO2007051926A1 Cytotoxic antibodies targeting antibodies inhibiting factor viii |
| 05/10/2007 | WO2007051805A2 Use of ceacam8-specific substances for treating autoimmune diseases and a method for screening substances which induce apoptosis |
| 05/10/2007 | WO2007051763A1 Prime boost vaccine for the protection of equines against equine influenza |
| 05/10/2007 | WO2007051476A1 Use of a liquid allergy vaccine formulation for oromucosal administration |
| 05/10/2007 | WO2007051316A1 Inhibition of autophagy genes in cancer chemotherapy |
| 05/10/2007 | WO2007031574A3 Therapeutic use of outer shigella protein f (os pf) |
| 05/10/2007 | WO2007022520A3 Antibody-mediated enhancement of immune response |
| 05/10/2007 | WO2007018564A3 Enhancement of b cell proliferation by il-15 |
| 05/10/2007 | WO2007018463A3 Interaction of moraxella catarrhalis with epithelial cells, extracellular matrix proteins and the complement system |
| 05/10/2007 | WO2007014169A3 Anti-cd26 antibodies and methods of use thereof |
| 05/10/2007 | WO2007013950A3 Combination therapy of her expressing tumors |
| 05/10/2007 | WO2007011873A3 Method for treating intraocular neovascular diseases |
| 05/10/2007 | WO2007007173A3 Human anti-madcam antibodies |
| 05/10/2007 | WO2007003904A3 Prophylactic and immunomodulatory compositions and uses |
| 05/10/2007 | WO2007002096A3 Methods and compositions for targeting ifnar2 |
| 05/10/2007 | WO2006134125A9 Antigen conjugates and uses thereof |
| 05/10/2007 | WO2006133148A3 Method of producing antibodies with modified fucosylation level |
| 05/10/2007 | WO2006131512A3 Anti-thrombotic agents |
| 05/10/2007 | WO2006123164A3 Lps-binding and bactericidal cytokines and interferons |
| 05/10/2007 | WO2006105597A8 Variants of hepatitis b virus with resistance to anti-viral nucleoside agents and applications thereof |
| 05/10/2007 | WO2006094974A3 Chemically defined stabiliser composition |